| [1] |
李星, 曾晓勇. 中国前列腺癌流行病学研究进展 [J]. 2021, 48(1): 98-102.
|
| [2] |
赫捷, 陈万青, 李霓, 等. 中国前列腺癌筛查与早诊早治指南(2022, 北京）[J]. 2022, 44(1): 29-53.
|
| [3] |
Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis[J]. N Engl J Med, 2018, 378(19): 1767-1777.
|
| [4] |
Rouviere O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study[J]. Lancet Oncol, 2019, 20(1): 100-109.
|
| [5] |
van der Leest M, Cornel E, Israel B, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study[J]. Eur Urol, 2019, 75(4): 570-578.
|
| [6] |
Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (primary): a prospective multicentre study[J]. Eur Urol, 2021, 80(6): 682-689.
|
| [7] |
Bell KJ, Del Mar C, Wright G, et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies[J]. Int J Cancer, 2015, 137(7): 1749-1757.
|
| [8] |
罗云, 高新. 2021版欧洲泌尿外科学会前列腺癌诊疗指南更新要点解读 [J/CD]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(2): 97-100.
|
| [9] |
Goel S, Shoag JE, Gross MD, et al. Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis[J]. Eur Urol Oncol, 2020, 3(1): 10-20.
|
| [10] |
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study[J]. Lancet, 2017, 389(10071): 815-822.
|
| [11] |
Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study[J]. J Urol, 2014, 192(1): 67-74.
|
| [12] |
Oerther B, Engel H, Bamberg F, et al. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level[J]. Prostate Cancer Prostatic Dis, 2022, 25(2): 256-263.
|
| [13] |
Padhani AR, Barentsz J, Villeirs G, et al. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway[J]. Radiology, 2019, 292(2): 464-474.
|
| [14] |
Drost FH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer[J]. Cochrane Database Syst Rev, 2019, 4(4): CD012663.
|
| [15] |
Schoots IG, Padhani AR, Rouviere O, et al. Analysis of magnetic resonance imaging-directed biopsy strategies for changing the paradigm of prostate cancer diagnosis[J]. Eur Urol Oncol, 2020, 3(1): 32-41.
|
| [16] |
Nordstrom T, Adolfsson J, Gronberg H, et al. Repeat prostate-specific antigen tests before prostate biopsy decisions[J]. J Natl Cancer Inst, 2016, 108(12): djw165.
|
| [17] |
Rosario DJ, Lane JA, Metcalfe C, et al. Contribution of a single repeat psa test to prostate cancer risk assessment: experience from the protect study[J]. Eur Urol, 2008, 53(4): 777-784.
|
| [18] |
De Nunzio C, Lombardo R, Nacchia A, et al. Repeat prostate-specific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer[J]. BJU Int, 2018, 122(1): 83-88.
|
| [19] |
Presti JC, Jr. Prostate biopsy: how many cores are enough?[J]. Urol Oncol, 2003, 21(2): 135-140.
|
| [20] |
Bryk DJ, Llukani E, Taneja SS, et al. The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy[J]. Urology, 2017, 102:178-182.
|
| [21] |
Freifeld Y, Xi Y, Passoni N, et al. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy[J]. Urol Oncol, 2019, 37(1): 57-62.
|
| [22] |
Tschirdewahn S, Wiesenfarth M, Bonekamp D, et al. Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography-fusion biopsy[J]. Eur Urol Focus, 2021, 7(6): 1300-1307.
|
| [23] |
Raman AG, Sarma KV, Raman SS, et al. Optimizing spatial biopsy sampling for the detection of prostate cancer[J]. J Urol, 2021, 206(3): 595-603.
|
| [24] |
Park MY, Park KJ, Lim B, et al. Comparison of biopsy strategies for prostate biopsy according to lesion size and PSA density in MRI-directed biopsy pathway[J]. Abdom Radiol (NY), 2020, 45(12): 4166-4177.
|
| [25] |
Hansen NL, Barrett T, Lloyd T, et al. Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy[J]. BJU Int, 2020, 125(2): 260-269.
|
| [26] |
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]. Lancet, 2020, 395(10231): 1208-1216.
|
| [27] |
Cornford P, Grummet J, Fanti S, et al. Prostate-specific membrane antigen positron emission tomography scans before curative treatment: ready for prime time?[J]. Eur Urol, 2020, 78(3): e125-e128.
|
| [28] |
Sgouros G, Bodei L, McDevitt MR, et al. Radiopharmaceutical therapy in cancer: clinical advances and challenges[J]. Nat Rev Drug Discov, 2020, 19(9): 589-608.
|
| [29] |
Willemse PM, Davis NF, Grivas N, et al. Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy[J]. Eur Urol, 2022, 81(4): 337-346.
|
| [30] |
Chu CE, Cowan JE, Fasulo V, et al. The clinical significance of multiple negative surveillance prostate biopsies for men on active surveillance-does cancer vanish or simply hide?[J]. J Urol, 2021, 205(1): 109-114.
|
| [31] |
Roach M, 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610[J]. J Clin Oncol, 2008, 26(4): 585-591.
|
| [32] |
Lawton CA, DeSilvio M, Roach M, 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions[J]. Int J Radiat Oncol Biol Phys, 2007, 69(3): 646-655.
|
| [33] |
Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol[J]. Lancet, 2022, 399(10323): 447-460.
|
| [34] |
Bubley GJ. Is the flare phenomenon clinically significant?[J]. Urology, 2001, 58(2 Suppl 1): 5-9.
|
| [35] |
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer[J]. N Engl J Med, 2020, 382(23): 2187-2196.
|
| [36] |
Kunath F, Jensen K, Pinart M, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer[J]. Cochrane Database Syst Rev, 2019, 6(6):CD003506.
|
| [37] |
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-psma-617 for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2021, 385(12): 1091-1103.
|